Table 5 Gender wise distribution of Genotype frequency and genetic model analysis for CDKN2B-AS1 rs2157719 among POAG and PACG cases with respect to control subjects
Males with POAG and PACG versus control male subjects | ||||||||
|---|---|---|---|---|---|---|---|---|
Genotypes | POAG n = 201 (%) | Control n = 226 (%) | p value | OR(CI) | PACG n = 52 (%) | Control n = 226 (%) | p value | OR(CI) |
CC | 10(4.9) | 34(15.04) | 0.0041* | 0.33(0.15–0.70) | 2(3.84) | 34(15.04) | 0.035* | 0.20(0.04–0.89) |
CT | 89(44.27) | 77(34.07) | 0.2 | 1.30(0.86–1.95) | 17(32.69) | 77(34.07) | 0.43 | 0.76(0.40–1.47) |
TT | 102(50.74) | 115(50.88) | Ref | Â | 33(63.46) | 115(50.88) | Ref | Â |
Genetic models | ||||||||
Dominant model | 99/102 | 111/115 | 0.97 | 1.00(0.68–1.47) | 19/33 | 111/115 | 0.1 | 0.59(0.32–1.11) |
Recessive model | 10/191 | 34/192 | 0.001* | 0.29(0.14–0.61) | 2/50 | 34/192 | 0.045* | 0.22(0.05–0.97) |
Additive model | 109/293 | 146/308 | 0.107 | 0.78(0.58–1.05) | 21/83 | 146/308 | 0.017* | 0.53(0.31–0.89) |
Females with POAG and PACG versus control female subjects | ||||||||
|---|---|---|---|---|---|---|---|---|
Genotypes | POAG n = 111 (%) | Control n = 216 (%) | p value | OR(CI) | PACG n = 95 (%) | Control n = 216 (%) | p value | OR(CI) |
CC | 9(8.10) | 30(13.88) | 0.17 | 0.56(0.25–1.27) | 5(5.26) | 30(13.88) | 0.029* | 0.32(0.11–0.89) |
CT | 48(43.24) | 84(38.80) | 0.75 | 1.07(0.66–1.75) | 38(40) | 84(38.88) | 0.64 | 0.88(0.53–1.47) |
TT | 54(48.64) | 102(47.22) | Ref | Â | 52(54.73) | 102(47.22) | Ref | Â |
Genetic models | ||||||||
Dominant model | 57/54 | 114/102 | 0.80 | 0.94(0.59–1.49) | 43/52 | 114/102 | 0.22 | 0.73(0.45–1.20) |
Recessive model | 9/102 | 30/186 | 0.13 | 0.54(0.25–1.19) | 5/90 | 30/186 | 0.033* | 0.34(0.12–0.91) |
Additive model | 66/156 | 144/288 | 0.350 | 0.84(0.59–1.20) | 48/142 | 144/288 | 0.045* | 0.67(0.46–0.99) |